Liminatus Pharma Inc. (NASDAQ:LIMN) Sees Significant Increase in Short Interest

Liminatus Pharma Inc. (NASDAQ:LIMN) was the recipient of a significant increase in short interest during the month of July. As of July 15th, there was short interest totaling 2,404,454 shares, an increase of 106.0% from the June 30th total of 1,167,107 shares. Based on an average trading volume of 75,297,149 shares, the short-interest ratio is currently 0.0 days. Approximately 5.9% of the company’s stock are sold short.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Liminatus Pharma in a research report on Wednesday, June 24th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, Liminatus Pharma currently has an average rating of “Sell”.

Liminatus Pharma Stock Down 3.6%

Shares of NASDAQ LIMN traded down $0.00 during midday trading on Thursday, hitting $0.10. The stock had a trading volume of 1,546,737 shares, compared to its average volume of 18,385,691. The business’s 50 day moving average is $0.13 and its 200-day moving average is $0.30. Liminatus Pharma has a 52 week low of $0.10 and a 52 week high of $6.84. The company has a market cap of $5.16 million, a P/E ratio of -0.23 and a beta of 5.62.

Liminatus Pharma (NASDAQ:LIMN) last announced its quarterly earnings results on Friday, May 15th. The company reported ($0.03) earnings per share for the quarter.

About Liminatus Pharma

Liminatus Pharma, Inc is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.